Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS).
“Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. “Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world’s most prestigious, breast cancer-focused organizations.”
In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program. Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer. The results suggest a distinct genetic background for hereditary cancer predisposition in the study population.
Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool. Christy Russell MD, VP Medical Affairs, Exact Sciences; Jennifer Racz, MD, Director, Oncology Medical Affairs, Exact Sciences; and Jay Andersen, MD, Co-Director, Compass Breast Specialists and Associate Chair, US Oncology Breast Cancer Research Committee; will review the development and validation of the RSClin Tool in patients with node-negative, early-stage breast cancer as well as discuss its utility for patients and providers.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.
SOURCE : PRNewswire